Increased food intake and energy expenditure following administration of olanzapine to healthy men

Obesity
Robert J FountaineDavid A Fryburg

Abstract

Atypical antipsychotic medications like olanzapine (OLZ) induce weight gain and increase the risk of diabetes in patients with schizophrenia. The goal of this study was to assess potential mechanisms of OLZ-induced weight gain and accompanying metabolic effects. Healthy, lean, male volunteers received OLZ and placebo (PBO) in a randomized, double-blind, crossover study. In periods 1 and 2, subjects received OLZ (5 mg for 3 days then OLZ 10 mg for 12 days) or matching PBO separated by a minimum 12-day washout. Twenty-four hour food intake (FI), resting energy expenditure (REE), activity level, metabolic markers, and insulin sensitivity (IS) were assessed. In total, 30 subjects were enrolled and 21 completed both periods. Mean age and BMI were 27 years (range: 18-49 years) and 22.6 +/- 2.2 kg/m(2), respectively. Relative to PBO, OLZ resulted in a 2.62 vs. 0.08 kg increase in body weight (P < 0.001) and 18% (P = 0.052 or 345 kcal) increase in FI. Excluding one subject with nausea and dizziness on the day of OLZ FI measurement, the increase in FI was 547 kcal, (P < 0.05). OLZ increased REE relative to PBO (113 kcal/day, P = 0.003). Significant increases in triglycerides, plasminogen activator inhibitor-I (PAI-I), leptin, and tumor ...Continue Reading

References

Mar 9, 1995·The New England Journal of Medicine·R L LeibelJ Hirsch
Jan 1, 1994·The Journal of Clinical Investigation·M K HellersteinD Faix
Mar 1, 1997·The Journal of Clinical Psychiatry·A P PopliG E Jaskiw
Apr 4, 1998·Obesity Research·B J RollsJ S Ulbrecht
Jun 1, 2000·The American Journal of Psychiatry·D C HendersonD C Goff
Jun 6, 2000·The American Journal of Clinical Nutrition·M RosenbaumR L Leibel
Dec 2, 2000·The American Journal of Clinical Nutrition·J A LevineM D Jensen
May 1, 2001·The American Journal of Psychiatry·F M TheisenJ Hebebrand
Jun 7, 2002·The Journal of Clinical Endocrinology and Metabolism·Margaret O SowellJamie Dananberg
Jul 11, 2002·Pharmacopsychiatry·M VirkkunenA Franssila-Kallunki
Jul 18, 2002·Obesity Reviews : an Official Journal of the International Association for the Study of Obesity·F L Greenway
Sep 25, 1959·Annals of the New York Academy of Sciences·R STEELE
Apr 9, 2005·The Journal of Clinical Psychiatry·Richard N Bergman, Marilyn Ader
Apr 13, 2005·Clinical Therapeutics·John W Newcomer
Jul 26, 2005·Physiology & Behavior·Annemiek M C P JoosenKlaas R Westerterp
Sep 15, 2005·Journal of Clinical Psychopharmacology·James L RoerigStephen A Wonderlich
Sep 21, 2005·The New England Journal of Medicine·Jeffrey A LiebermanUNKNOWN Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Jul 11, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Helliner S VestriW Timothy Garvey
Sep 19, 2007·The Journal of Clinical Psychiatry·Timothy E Wilens, Himanshu P Upadhyaya
Jan 1, 2008·Schizophrenia Bulletin·Othman SentissiMarie-France Poirier
Feb 23, 2008·Chronobiology International·Lorenzo TonettiVincenzo Natale
May 16, 2008·Journal of Clinical Psychopharmacology·Rocio Perez-IglesiasBenedicto Crespo-Facorro
Nov 13, 2009·The Journal of Clinical Endocrinology and Metabolism·Solrun VidarsdottirHanno Pijl

❮ Previous
Next ❯

Citations

May 11, 2011·International Journal of Obesity : Journal of the International Association for the Study of Obesity·E M van der ZwaalR A H Adan
May 31, 2012·Child and Adolescent Psychiatry and Mental Health·Chadi Albert CalargeBridget Zimmerman
Jan 3, 2012·Metabolism: Clinical and Experimental·Subin ParkJin Pyo Hong
Jun 15, 2011·Physiology & Behavior·Karen L Teff, Sangwon F Kim
Dec 28, 2010·Trends in Molecular Medicine·Christoph U CorrellAnil K Malhotra
Apr 27, 2012·International Journal of Mental Health Nursing·Agustin J Simonelli-MuñozSerafin Balanza
Jun 19, 2015·Current Diabetes Reports·Pornpoj Pramyothin, Lalita Khaodhiar
Nov 11, 2016·Saudi Pharmaceutical Journal : SPJ : the Official Publication of the Saudi Pharmaceutical Society·Rehmat ShahKhwaja Fawad
Jul 21, 2010·Neurochemistry International·Takahira YamauchiAkio Wanaka
Sep 6, 2014·Trends in Endocrinology and Metabolism : TEM·Jacob S BallonJeffrey A Lieberman
Oct 10, 2013·The International Journal of Neuropsychopharmacology·E M van der ZwaalR A H Adan
Jun 3, 2016·Psychopharmacology·Louise BenarrochMargaret K Hahn
Jun 22, 2017·Twin Research and Human Genetics : the Official Journal of the International Society for Twin Studies·Anna Janina EngstlerIna Bergheim
Sep 25, 2018·The Cochrane Database of Systematic Reviews·Anna SutherlandBee Wee
Feb 21, 2019·The British Journal of Psychiatry : the Journal of Mental Science·Scott B TeasdaleTracy L Burrows
Nov 1, 2013·Journal of Cancer Research and Clinical Oncology·Sierra VigMyke R Green
Jun 28, 2019·Nutrition & Dietetics : the Journal of the Dietitians Association of Australia·Scott B TeasdalePhilip B Ward
Jul 25, 2019·Issues in Mental Health Nursing·Raquel CostaRui Corredeira
Oct 9, 2013·Journal of Clinical Psychopharmacology·Margaret Karolina HahnGary J Remington
Apr 23, 2020·Endocrinology, Diabetes & Metabolism·Avital NahmiasSatya Dash
Aug 15, 2017·Frontiers in Neuroscience·Zachary FreybergJacob S Ballon
Jun 6, 2021·Eating and Weight Disorders : EWD·Christina HorsagerSøren Dinesen Østergaard
Sep 3, 2021·Canadian Journal of Physiology and Pharmacology·Ghada S MahmoudSally A Sayed
Dec 24, 2020·Nutrients·Nicolette StogiosMargaret K Hahn

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here